Universite de Paris
259 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Recorded as renamed to Université Paris Cité (2022)
0
Ending by 2030
Feb 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 13, 2027The maintenance fee for Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction (US 10,376,484) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 2 fees due Jun 26, 2027
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 5 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,376,484 | Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction In force · From the USPTO record | In force | From the USPTO record | |
| US 11,383,004 | Methods for Adhering Tissue Surfaces and Materials and Biomedical Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,710,045 | Capsules Containing Mammalian Cells In force · High confidence | In force | High confidence | |
| US 12,427,141 | BYL719 (ALPELISIB) for Use in the Treatment of PIK3CA-RELATED Overgrowth Spectrum (Pros-Cloves Syndrome) In force · High confidence | In force | High confidence | |
| US 10,842,776 | Hycanthone Derivatives and Primaquine Derivatives for Use in the Prevention And/Or the Treatment of Disorders Associated to Gammaherpesvirus In force · High confidence | In force | High confidence | |
| US 11,638,723 | Method for Generating T Cells Progenitors In force · High confidence | In force | High confidence | |
| US 11,642,376 | Method for Generating T Cell Progenitors In force · High confidence | In force | High confidence | |
| US 12,599,662 | Methods and Compositions for Treating Cancers In force · High confidence | In force | High confidence | |
| US 12,778,952 | Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy In force · High confidence | In force | High confidence | |
| US 11,854,801 | Method and Device for Depositing a Nano-Object In force · High confidence | In force | High confidence |
Also on record, not counted in the 24: 259 patents in force now held by others · 55 lapsed for an unpaid fee · 9 ended at full term · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
44 pending · 66 abandoned